Blueprint Medicines (BPMC)
(Delayed Data from NSDQ)
$93.00 USD
+2.27 (2.50%)
Updated Apr 26, 2024 04:00 PM ET
After-Market: $93.00 0.00 (0.00%) 7:58 PM ET
2-Buy of 5 2
F Value D Growth C Momentum F VGM
Fundamental Charts
About PEG Ratio (TTM)
The company's trailing twelve month (TTM) PEG ratio is the P/E ratio divided by its long-term growth rate consensus. This ratio essentially compares the P/E to its growth rate, thus, for many, telling a more complete story than just the P/E ratio alone. Conventional wisdom says that a PEG ratio of 1 or less is considered good (at par or undervalued to its growth rate). A value greater than 1, in general, is not as good (overvalued to its growth rate). For example, a company with a P/E ratio of 25 and a growth rate of 20% would have a PEG ratio of 1.25 (25 / 20 = 1.25). A company with a P/E ratio of 40 and a growth rate of 50% would have a PEG ratio of 0.80 (40 / 50 = 0.80). Traditionally, investors would look at the stock with the lower P/E and deem it a bargain. But when compared to its growth rate, it doesn't have the earnings growth to justify its P/E. In this example, the one with the P/E of 40 is the better bargain because it is selling at a discount to its growth rate. So the PEG ratio tells you what you're paying for each unit of earnings growth.
BPMC 93.00 +2.27(2.50%)
Will BPMC be a Portfolio Killer in April?
Zacks Investment Research is releasing its prediction for BPMC based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for BPMC
Factors Setting the Tone for Ecolab's (ECL) Q1 Earnings
Blueprint Medicines (BPMC) Expected to Beat Earnings Estimates: What to Know Ahead of Q1 Release
BPMC: What are Zacks experts saying now?
Zacks Private Portfolio Services
CRISPR Therapeutics (CRSP) Down 13.6% Since Last Earnings Report: Can It Rebound?
Why Is Halozyme Therapeutics (HALO) Up 5.3% Since Last Earnings Report?
Moderna (MRNA) Soars 8.7%: Is Further Upside Left in the Stock?
Other News for BPMC
The Analyst Verdict: Blueprint Medicines In The Eyes Of 7 Experts
Stifel Nicolaus Sticks to Their Buy Rating for Blueprint Medicines (BPMC)
Blueprint Medicines price target raised by $10 at Stifel, here's why
Analysts Offer Insights on Healthcare Companies: Hookipa Pharma (HOOK), Praxis Precision Medicines (PRAX) and Blueprint Medicines (BPMC)
Barclays Sticks to Its Hold Rating for Blueprint Medicines (BPMC)